Select Publications
Journal articles
, 2012, 'Rapid-throughput skeletal phenotyping of 100 knockout mice identifies 9 new genes that determine bone strength', PLoS Genetics, 8, pp. e1002858, http://dx.doi.org/10.1371/journal.pgen.1002858
, 2012, 'Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma', PLoS One, 7, pp. e41127, http://dx.doi.org/10.1371/journal.pone.0041127
, 2012, 'Targeting tumour-initiating cells with TRAIL based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo', PLoS One, 7, pp. e35830, http://dx.doi.org/10.1371/journal.pone.0035830
, 2011, 'Bisphosphonates in preclinical bone oncology', Bone, 49, pp. 66 - 70, http://dx.doi.org/10.1016/j.bone.2010.11.017
, 2011, 'Glycogen synthase kinase-3α/β inhibition promotes in vivo amplification of endogenous mesenchymal progenitors with osteogenic and adipogenic potential and their differentiation to the osteogenic lineage', Journal of Bone and Mineral Research, 26, pp. 811 - 821, http://dx.doi.org/10.1002/jbmr.266
, 2011, 'Hedgehog signalling is required for perichondral osteoblast differentiation in zebrafish', Mechanisms of Development, 128, pp. 141 - 152, http://dx.doi.org/10.1016/j.mod.2010.11.006
, 2011, 'Tumor-host cell interactions in the bone disease of myeloma', Bone, 48, pp. 121 - 128, http://dx.doi.org/10.1016/j.bone.2010.06.029
, 2011, 'Deregulation of the bone marrow stromal compartment occurs early in multiple myeloma and precedes osteolytic bone disease', Bone, 48, pp. S253 - S254, http://dx.doi.org/10.1016/j.bone.2011.03.619
, 2011, 'Laser-capture micro-dissection and gene array analysis to identify new molecules implicated in the development of myeloma bone disease', Bone, 48, pp. S19 - S19, http://dx.doi.org/10.1016/j.bone.2010.10.049
, 2011, 'Mechanisms of osteoblast supression in multiple myeolma', Bone, 48, pp. S37 - S37, http://dx.doi.org/10.1016/j.bone.2010.10.103
, 2011, 'Multiphoton imaging of individual myeloma cells in calvariae: Association of myeloma development with sites of bone turnover', Bone, 48, pp. S14 - S14, http://dx.doi.org/10.1016/j.bone.2010.10.037
, 2011, 'Targeting tumour-initiating cells with trail based combination therapy ensures complete and lasting eradication of multiple myeloma tumours in vivo', Bone, 48, pp. S15 - S15, http://dx.doi.org/10.1016/j.bone.2010.10.040
, 2010, 'Bisphosphonate therapy in the treatment of multiple myeloma', Current Pharmaceutical Design, 16, pp. 3028 - 3036, http://dx.doi.org/10.2174/138161210793563608
, 2010, 'Metastasis and bone loss: Advancing treatment and prevention', Cancer Treatment Reviews, 36, pp. 615 - 620, http://dx.doi.org/10.1016/j.ctrv.2010.04.003
, 2010, 'The Effect of Myeloma Cells on Bone Homeostasis Is Heterogenous and Correlates with Underlying Genetic Lesions and Bone Disease In Vivo', Blood, 116, pp. 4052 - 4052, http://dx.doi.org/10.1182/blood.v116.21.4052.4052
, 2010, 'Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis', Arthritis Research and Therapy, 12, http://dx.doi.org/10.1186/ar3098
, 2010, 'Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes', Leukemia Research, 34, pp. 742 - 751, http://dx.doi.org/10.1016/j.leukres.2009.10.016
, 2010, 'Optimal bone strength and mineralization requires the type 2 iodothyronine deiodinase in osteoblasts', Proceedings of the National Academy of Sciences of the United States of America, 107, pp. 7604 - 7609, http://dx.doi.org/10.1073/pnas.0911346107
, 2010, 'Fas receptor is required for estrogen deficiency-induced bone loss in mice', Laboratory Investigation, 90, pp. 402 - 413, http://dx.doi.org/10.1038/labinvest.2009.144
, 2010, 'Regulation of neural crest cell fate by the retinoic acid and Pparg signalling pathways', Development, 137, pp. 389 - 394, http://dx.doi.org/10.1242/dev.044164
, 2010, 'Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo', Journal of Bone and Mineral Research, 25, pp. 2633 - 2646, http://dx.doi.org/10.1002/jbmr.142
, 2010, 'Targeting RANK/RANKL in the treatment of solid tumours and myeloma', Current Pharmaceutical Design, 16, pp. 1272 - 1283, http://dx.doi.org/10.2174/138161210791034021
, 2009, 'Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.', Blood, 114, pp. 298 - 298, http://dx.doi.org/10.1182/blood.v114.22.298.298
, 2009, 'The use of bisphosphonates in multiple myeloma: Recommendations of an expert panel on behalf of the European Myeloma Network', Annals of Oncology, 20, pp. 1303 - 1317, http://dx.doi.org/10.1093/annonc/mdn796
, 2009, 'Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790', International Journal of Cancer, 125, pp. 1177 - 1185, http://dx.doi.org/10.1002/ijc.24436
, 2009, 'Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: Effect on myeloma bone disease in the 5T2MM murine model of myeloma', Cancer Research, 69, pp. 5307 - 5311, http://dx.doi.org/10.1158/0008-5472.CAN-08-4472
, 2009, 'Inhibiting dickkopf-1 (Dkkl) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma', Journal of Bone and Mineral Research, 24, pp. 425 - 436, http://dx.doi.org/10.1359/jbmr.081104
, 2009, 'Tracking gene expression during zebrafish osteoblast differentiation', Developmental Dynamics, 238, pp. 459 - 466, http://dx.doi.org/10.1002/dvdy.21838
, 2009, 'The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models', Leukemia, 23, pp. 1894 - 1903, http://dx.doi.org/10.1038/leu.2009.121
, 2009, '13-P049 FGF signalling is regulating bone development in zebrafish', Mechanisms of Development, 126, pp. S209 - S209, http://dx.doi.org/10.1016/j.mod.2009.06.522
, 2009, 'B144 The Effect of JNJ-26481585 in Murine Myeloma Models', Clinical Lymphoma and Myeloma, 9, pp. S104 - S104, http://dx.doi.org/10.1016/s1557-9190(11)70664-3
, 2009, 'Blockade of the ALK1 receptor reduces tumour microvessel density and prevents the formation of osteolytic bone disease in the 5T2MM murine model of myeloma', Bone, 44, pp. S55 - S55, http://dx.doi.org/10.1016/j.bone.2009.01.465
, 2009, 'Genetic models of bone disease using ENU mutagenesis', Bone, 44, pp. S19 - S19, http://dx.doi.org/10.1016/j.bone.2009.01.041
, 2009, 'Inhibiting glycogen synthase kinase-3 (GSK-3) prevents the development of myeloma bone disease', Bone, 44, pp. S53 - S54, http://dx.doi.org/10.1016/j.bone.2009.01.462
, 2009, 'Localising individual myeloma cells to the myeloma ‘niche’ in bone using multiphoton microscopy', Bone, 44, pp. S164 - S164, http://dx.doi.org/10.1016/j.bone.2009.01.384
, 2009, 'Soluble RANK ligand produced by myeloma cells contributes to generalised bone loss in multiple myeloma', Bone, 44, pp. S162 - S162, http://dx.doi.org/10.1016/j.bone.2009.01.458
, 2009, 'Tracking gene expression during zebrafish osteoblast differentiation', Developmental Dynamics, 238, http://dx.doi.org/10.1002/dvdy.21904
, 2008, 'Geranylgeranyl transferase type II inhibition prevents myeloma bone disease', Biochemical and Biophysical Research Communications, 377, pp. 453 - 457, http://dx.doi.org/10.1016/j.bbrc.2008.09.157
, 2008, 'Erratum: The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis (Leukemia (2008) vol. 22 (2247-2256) 10.1038/ leu.2008.2256)', Leukemia, 22, pp. 2292, http://dx.doi.org/10.1038/leu.2008.288
, 2008, 'Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension', American Journal of Pathology, 172, pp. 256 - 264, http://dx.doi.org/10.2353/ajpath.2008.070395
, 2008, 'The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis', Leukemia, 22, pp. 2247 - 2256, http://dx.doi.org/10.1038/leu.2008.235
, 2008, 'OC7. Inhibiting dickkopf-1 (Dkk-1) prevents the development of osteolytic bone disease in multiple myeloma', Cancer Treatment Reviews, 34, pp. 52 - 52, http://dx.doi.org/10.1016/j.ctrv.2008.03.033
, 2008, 'P1. Breast cancer cells cause a reduction in osteoblast number – An early event in the development of osteolytic bone lesions', Cancer Treatment Reviews, 34, pp. 12 - 12, http://dx.doi.org/10.1016/j.ctrv.2008.03.042
, 2008, 'P3. A soluble activin type II receptor prevents the development of myeloma bone disease', Cancer Treatment Reviews, 34, pp. 13 - 14, http://dx.doi.org/10.1016/j.ctrv.2008.03.044
, 2007, 'In Vivo Evaluation of a BAFF Inhibitor AMG 523 Suggests Lack of Efficacy in Multiple Myeloma Tumor Models.', Blood, 110, pp. 1518 - 1518, http://dx.doi.org/10.1182/blood.v110.11.1518.1518
, 2007, 'Investigating the interaction between osteoprotegerin and receptor activator of NF-κB or tumor necrosis factor-related apoptosis-inducing ligand: Evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways', Journal of Biological Chemistry, 282, pp. 31601 - 31609, http://dx.doi.org/10.1074/jbc.M706078200
, 2007, 'Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: Beneficial effects on tumor growth, angiogenesis, bone disease and survival', International Journal of Cancer, 121, pp. 1857 - 1861, http://dx.doi.org/10.1002/ijc.22845
, 2007, 'Myeloma bone disease and proteasome inhibition therapies', Blood, 110, pp. 1098 - 1104, http://dx.doi.org/10.1182/blood-2007-03-067710
, 2007, 'Inhibition of p38α mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma', Cancer Research, 67, pp. 4572 - 4577, http://dx.doi.org/10.1158/0008-5472.CAN-06-4361
, 2007, 'Apomine™, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo', International Journal of Cancer, 120, pp. 1657 - 1663, http://dx.doi.org/10.1002/ijc.22478